Phase 1b Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase of Trial: Phase I
Latest Information Update: 22 Nov 2019
Price : $35 *
At a glance
- Drugs Dinaciclib (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 26 Sep 2019 Planned number of patients changed from 44 to 48.
- 05 Jun 2019 Planned number of patients changed from 48 to 44.
- 10 May 2019 Planned End Date changed from 8 Jun 2021 to 5 Oct 2021.